GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Common Stock

Cambium Bio (ASX:CMB) Common Stock : A$43.63 Mil (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Common Stock?

Cambium Bio's quarterly common stock stayed the same from Jun. 2023 (A$38.62 Mil) to Dec. 2023 (A$38.62 Mil) but then increased from Dec. 2023 (A$38.62 Mil) to Jun. 2024 (A$43.63 Mil).

Cambium Bio's annual common stock stayed the same from Jun. 2022 (A$38.62 Mil) to Jun. 2023 (A$38.62 Mil) but then increased from Jun. 2023 (A$38.62 Mil) to Jun. 2024 (A$43.63 Mil).


Cambium Bio Common Stock Historical Data

The historical data trend for Cambium Bio's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cambium Bio Common Stock Chart

Cambium Bio Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.16 38.29 38.62 38.62 43.63

Cambium Bio Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.62 38.62 38.62 38.62 43.63

Cambium Bio Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cambium Bio Business Description

Traded in Other Exchanges
N/A
Address
16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines